Herbal, Prescribed, and Over-the-Counter Drug Use in Older Women: Prevalence of Drug Interactions

Geriatric Nursing

Volumn 27, Issue 2, 2006, Pages 118-129

  Yoon, Saunjoo L ^a   Schaffer, Susan D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; DRUG INTERACTION; DRUG UTILIZATION; EDUCATION; EPIDEMIOLOGY; FEMALE; GERIATRIC ASSESSMENT; HUMAN; PATIENT ATTITUDE; PHYTOTHERAPY; PRESCRIPTION; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; RISK FACTOR; SELF MEDICATION; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG INTERACTIONS; DRUG UTILIZATION; DRUGS, NON-PRESCRIPTION; FEMALE; FLORIDA; GERIATRIC ASSESSMENT; HEALTH CARE SURVEYS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PHYTOTHERAPY; PRESCRIPTIONS, DRUG; RISK ASSESSMENT; RISK FACTORS; SELF MEDICATION; WOMEN;

EID: 33645907535     PISSN: 01974572     EISSN: 15283984     Source Type: Journal    
DOI: 10.1016/j.gerinurse.2006.02.014     Document Type: Article

References (59)

1. Kelly J.P., Kaufman D.W., Kelley K., et al. Recent trends in use of herbal and other natural products. Arch Int Med 165 (2005) 281-286
2. Bruno J.J., and Ellis J.J. Herbal use among U.S. elderly. 2002 National Health Interview Survey. Ann Pharmacother 39 (2005) 643-648
3. Eskin S.B. Dietary supplements and older consumers. Data Digest 66 (2001) 1-8 AARP Public Policy Institute: Washington, DC
4. Yoon S.L., and Horne C.H. Herbal products and conventional medicines used by community-residing older women. J Adv Nurs 33 (2001) 51-59
5. Yoon S.L., Horne C.H., and Adams C. Herbal product use by African American older women. Clin Nurs Res 13 (2004) 271-288
6. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997. results of a follow-up national survey. JAMA 280 (1998) 1569-1575
7. Solberg L.I., Hurley J.S., Roberts M.H., et al. Measuring patient safety in ambulatory care. potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care 10 (2004) 753-759
8. Kaufman D.W., Kelly J.P., Rosenberg L., et al. Recent patterns of medication use in the ambulatory adult population of the United States. the Slone survey. JAMA 287 (2002) 337-344
9. Turnheim K. Drug dosage in the elderly. is it rational?. Drugs Aging 13 (1998) 357-379
10. Turnheim K. Drug therapy in the elderly. Exp Gerontol 39 (2004) 1731-1738
11. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal drugs. N Engl J Med 340 (1999) 1888-1899
12. Johnson A.G. NSAIDs and increased blood pressure. What is the clinical significance?. Drug Safety 17 (1997) 277-289
13. Peng C.C., Glassman P.A., Marks I.R., et al. Retrospective drug utilization review. incidence of clinically relevant potential drug-drug interactions in a large ambulatory populations. J Manag Care Pharm 9 (2003) 513-522
14. Yoon S.L. Use of herbal products, prescribed medicines and non-prescribed medicines by community-dwelling older women (1999), Doctoral dissertation, University of Florida Diss Abstracts Int 60:W4Y591u1999.
15. Vaes L.P., and Chyka P.A. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng. nature of the evidence.Review. Ann Pharmacother 34 (2000) 1478-1482
16. U.S. Department of Health and Human Services, Food and Drug Administration, 21 CFR Part 343 (docket no. 77N-094A). Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products (2005). http://www.fda.gov/ohrms/dockets/ac/02/briefing/3882b1_01_F-Professional%20Labeling.pdf www.fda.gov/ohrms/dockets/ac/02 /briefing/3882b1_01_F-Professional%20Labeling.pdf. Cited October 6
17. Murphey L.M., and Hood E.H. Bosentan and warfarin interaction. Ann Pharmacother 37 (2003) 1028-1031
18. Gugler R., and Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet 18 (1990) 210-219
19. Singh N., Weisler S.L., and Hershman J.M. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid 11 (2001) 967-971
20. PDR Electronic Library. Thomson Micromedex; 2002-2006 (2005). http://www.thomsonhc.com/pdrel/librarian www.thomsonhc.com/pdrel/librarian Cited October 6
21. Hansten P.D., and Horn J.R. Cytochrome P450 enzymes and drug interactions, table of cytochrome P450 substrates, inhibitors, inducers and P-glycoprotein and footnotes. The top 100 drug interactions-a guide to patient management (2005), H&H publications, Edmonds, WA 157-170
22. Henderson L., Yue Q.Y., Bergquist C., et al. St John's wort (Hypericum perforatum). drug interactions and clinical outcomes. Br J Clin Pharmacol 54 (2002) 349-356
23. U.S. Food and Drug Administration. Draft guidance for industry labeling for noncontraceptive estrogen drug products. Document No. 5670. Division of Dockets Management (HFA-305). Rockville, MD: Food and Drug Administration.Available atwww.fda.gov/cder/guidance/5670dft.pdfAccessed October 6, 2005
24. Sperber A.D., and Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Int Med 152 (1992) 183-184
25. Yue Q.Y., Bergquist C., and Gerden B. Seven cases of decreased effect of warfarin during concomitant treatment with St. John's wort (correspondence). Lancet 355 (2000) 576-577
26. Ang-Lee M.K., Moss J., and Yuan C.S. Herbal medicines and perioperative care. JAMA 286 (2001) 208-216
27. Kurtovic J., and Riordan S.M. Paracetamol-induced hepatotoxicity at recommended dosage. J Intern Med 253 (2003) 240-243
28. Boesgaard S., Nielsen-Kudsk J.E., Laursen J.B., and Aldershvile J. Thiols and nitrates. reevaluation of the thiol depletion theory of nitrate tolerance. Am J Cardiol 81 (1998) 21A-29A
29. Package insert. Macrodantin (nitrofurantoin macrocrystals). Cincinnati, OH: Proctor & Gamble Pharmaceuticals.
30. Naggar V.F., and Khalil S.A. Effect of magnesium trisilicate on nitrofurantoin absorption. Clin Pharmacol Ther 25 (1979) 857-863
31. Roth T., and Roehrs T.A. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 52 (1991) 38-41
32. Ariga T., Oshiba S., and Tamada T. Platelet aggregation inhibitor in garlic. Lancet 1 (1981) 150-151
33. Nurtjahja-Tjendraputra E., Ammit A.J., Roufogalis B.D., et al. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res 111 (2003) 259-265
34. Frishman W.H. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 89 (2002) 18D-25D
35. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. National Institute of Health publication No. 99-4080 (1997) 1-64
36. Package insert. Florinef Acetate (fludrocortisone acetate). Bristol, TN: Monarch Pharmaceuticals.
37. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 115 (1991) 787-796
38. Burke A., Smyth E.M., and FitzGerald G.A. Analgesic-antipyretic agents. pharmacotherapy of gout. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. (2006), McGraw Hill, New York 671-715
39. Dalton S.O., Johansen C., Mellemkjaer L., et al. Use of selective serotonin reuptake inhibitors and the risk of upper gastrointestinal tract bleeding. a population-based cohort study. Arch Intern Med 163 (2003) 59-64
40. Fored C.M., Ejerblad E., Lindblad P., et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345 (2001) 1801-1808
41. Miners J.O. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 17 (1989) 327-344
42. Lamant V., Mauco G., Braquet P., et al. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba. Bio Pharmacol 36 (1987) 2749-2752
43. Teng C.M., Kuo S.C., Ko F.N., et al. Antiplatelet actions of panaxynol and ginsenosides isolated from ginseng. Biochem Biophys Acta 990 (1989) 315-320
44. Smith M., Lin K.M., and Zheng Y.P. An open trial of nifedipine-herb interactions. nifedipine with St. John's wort, ginseng, or Ginkgo biloba. [abstract]. Clin Pharmacol Ther 69 (2001) P86
45. Sheela C.G., Kumud K., and Augusti K.T. Anti-diabetic effects of onion and garlic sulfoxide amino acids in rats. Planta Med 61 (1995) 356-357
46. Package insert. Deltasone (prednisone). Kalamazoo, MI: Pharmacia & Upjohn Co.
47. Welch M.J., Meltzer E.O., and Simons F.E. H1-antihistamines and the central nervous system. Clin Allergy Immunol 17 (2002) 337-388
48. Dordoni B., Wilson R.A., Thompson R.P.H., et al. Reduction of absorption of paracetamol by activated charcoal and cholestyramine. a possible therapeutic measure. BMJ 3 (1973) 86-87
49. Seixas F.A. Alcohol and its drug interactions. Ann Intern Med 83 (1975) 86-92
50. Soll A.H., and Practice Parameters Committee of the American College of Gastroenterology. Medical treatment of peptic ulcer disease. practice guidelines. JAMA 275 (1996) 622-629
51. Package insert. Antivert (meclizine). New York: Pfizer.
52. Hoffman B.B., and Lefkowitz R.J. Atropine, scopolamine, and related antimuscarinic drugs. In: Gilman A.G., Rall T.W., Nies A.S., and Taylor P. (Eds). Goodman and Gilman's pharmacological basis of therapeutics. 8th ed. (1990), Pergamon Press, New York 150-161
53. Catella-Lason F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
54. Taha A.S., Angerson W.A., Knill-Jones R.P., et al. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs-a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 22 (2005) 285-289
55. Tarone R.E., Blot W.J., and McLaughlin J.K. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding. relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 11 (2004) 17-25
56. Stockl K., Cyprien L., and Chang E.Y. Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm 11 (2005) 550-558
57. Lanas A. Gastrointestinal injury from NSAID therapy. how to reduce the risk of complications. Postgrad Med 117 6 (2005) 23-31
58. Kimmey M.B., and Lanas A. Review article. appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 19 (2004) 60-65
59. Gora M., Seth S., Bay W., et al. Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. Clin Pharm 8 (1989) 227-229